Dear Editor,

We read with interest the article “Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis” (Ann Hematol 100, 725–734 [2021]). Such an article is important for decision-making to inform clinicians of the most effective and safe treatments in a complex setting such as relapsed refractory multiple myeloma (MM). However, all such studies should be conducted in line with recognized guidance [1, 2], and caution is warranted in the interpretation of this study as there are a number of serious methodological and data concerns that limit the validity of the conclusions.

The systematic literature review that was conducted to identify phase III studies was originally restricted to include only lenalidomide or bortezomib in the control arm. Fifteen such studies were identified. However, this protocol was violated when “two studies with pomalidomide and one with carfilzomib in the control arm were also included.”

Furthermore, the principles which underpin the network meta-analysis (NMA) methodology are violated on multiple levels:

- Trials evaluating different populations without any adjustment for treatment effect modifiers are compared.
- Studies were conducted over at least a 15-year period, during which drug availability and standard of care treatment regimens varied considerably.
- Different backbone therapies are “considered equivalent therapies” and combined as a single “control” group.
- Severe adverse events (SAE) are assumed to be comparable with grade III/IV events.

It is well documented that patient characteristics (i.e., age, performance status, cytogenetic risk), number of prior treatment lines, type of therapies received, and refractoriness to treatment options may act as prognostic factors and treatment effect modifiers. However, study inclusion criteria vary from no refractory patients (DOXIL-MMY-3001) to all patients were refractory (ICARIA), and the median number of prior lines of therapy ranged from 1 to 3 (see Table 1).

Lenalidomide and bortezomib are routinely used in clinical practice for MM treatment, including in combination. Assuming all control backbone therapies are “equivalent” when the efficacy differs substantially between studies invalidates this approach, as shown for example by the PFS of CASTOR (Vd) vs POLLUX (Rd). It fails to accurately capture their respective benefit and the role they may play in the efficacy of the regimen. This is also relevant for ICARIA, CANDOR, and KEYNOTE-183, which included neither lenalidomide nor bortezomib in the treatment regimens, but still had their backbone therapies combined for inclusion in the NMA.

This equivalency assumption is likely to also skew the interventional treatment’s adverse event (AE) profile, which may be over- or underestimated based on the backbone regimen. Further, results of the toxicity comparison are rendered misleading by using grade III/IV events interchangeably with SAEs. These two terminologies have distinct definitions and capture different aspects of treatment toxicity. AEs are graded I–V, and seriousness of the event is determined independently of the grade. Generally, the occurrence of grade III/IV AEs is higher than SAEs.

In conclusion, we commend the authors in attempting to address an important open question in the treatment of
Table 1  Overview of the studies included in the NMA by Arcuri and Americo (2021)

| Study       | Intervention (n) | Control (n) | Patient population | Median number of prior treatment lines | Bortezomib refractory | Lenalidomide refractory | Refractory to lenalidomide and bortezomib | Adverse events source in NMA |
|-------------|------------------|-------------|--------------------|----------------------------------------|------------------------|------------------------|------------------------------------------|----------------------------|
| VANTAGE 088 [3] | VorV (n=317)     | V (n=320)   | 1-3 prior regimens | 2 prior regimens                       | +                     | −                      | −                                        | SAE                        |
| POLLUX [4]  | DRd (n=286)       | Rd (n=283)  | 1+                 | 1 (1–11)                               | + + + *               | + *                    | + + †                                    | SAE                        |
| ENDEAVOR [5] | Rd (n=464)        | Vd (n=465)  | 1+                 | 2 (1–2)                                | + +                    | −                      | + +                                      | SAE                        |
| TOURMALINE-MM1 [6] | NRD (n=360)   | Rd (n=362)  | 1–3                | 1 prior: 62%                           | + + +                  | +                    | −                                        | SAE                        |
| TOURMALINE MM1-China [7] | NRd (n=57)  | Rd (n=58)   | 1–3                | 1 prior: 44%                           | + +                    | +                      | −                                        | SAE                        |
| NCT00813510 [8] | CyVd (n=46)    | Vd (n=47)   | 1+                 | 1 prior: 57%                           | NR                    | NR                     | NR                                       | SAE                        |
| ELOQUENT-2 [9] | ERd (n=321)      | Rd (n=325)  | 1–3                | 2 (1–4)                                | + + +                  | +                      | −                                        | SAE                        |
| KEYNOTE-183 [10] | PembroPd (n=125) | Pd (n=124)  | 2+including IMiD and PIs | 3 (1–3)                              | + + + +                 | + + + +          | + + + †                                    | SAE                        |
| DOXIL-MMY-3001 [11] | PEG-Dox (n=324) | V (n=322)   | 1+                 | 66% received 2+therapies               | −                     | −                      | −                                        | SAE                        |
| CASTOR [12] | DVd (n=251)       | Vd (n=247)  | 1+                 | 2 (1–9)                                | + + *                  | −                      | −                                        | Grade III/IV               |
| OPTIMISM [13] | PVd (n=281)       | Vd (n=278)  | 1–3                | 1 (1–3)                                | + + +                  | +                      | + +                                      | SAE                        |
| PANORAMA-1 [14] | PanVd (n=387)  | Vd (n=381)  | 1–3 treatments     | 1 (1–3)                                | + +                    | +                      | NR                                       | SAE                        |
| ASPIRE [15] | KRd (n=396)       | Rd (n=396)  | 1–3                | 2 (1–3)                                | + +                    | −                      | +                                        | SAE                        |
| BELLINI [16] | VenVd (n=194)     | Vd (n=197)  | 1–3                | NR ‡                                    | + + *                  | NR                     | +                                        | SAE                        |
| GMGMG ReLApE [17] | ASCT-Rd (n=139) | Rd (n=138)  | 1–3                | 1 prior: 94%                           | + + + +                 | −                      | −                                        | SAE                        |
| BOSTON [18]  | SVd (n=195)       | Vd (n=207)  | 1–3 prior regimens | 2 (1–2)                                | + + +                  | −                      | −                                        | SAE but stated as NR        |
| CANDOR [19]  | DKd (n=312)       | Kd (n=154)  | 1–3 prior therapies | 2 (1–2)                                | + + +                  | +                      | NR                                       | SAE                        |
| ICARIA-MM [20] | IsaPd (n=154) | Pd (n=153)  | 2+and have not responded to R or a PI | 3 (2–4)                | + + + + +               | + + + +                    | + + + + + + †                  | Grade III/IV               |

+1–33%; + 34–66%; + 67–100%  
−0%

*Based on prior exposure to a proteasome inhibitor.
†Based on prior exposure to an immunomodulatory drug.
‡Trial excluded lenalidomide refractory patients however some patients appear to have been enrolled.
§Patients were considered refractory if two (double: lenalidomide and bortezomib), three (triple: lenalidomide, bortezomib, and pomalidomide or lenalidomide, bortezomib, and carfilzomib), or four (quadruple: lenalidomide, bortezomib, pomalidomide, and carfilzomib) previous lines of treatment were ineffective, defined as documented disease progression during or within 60 days of completing their last anti-myeloma therapy.
¶In the VenV arm, 47% of patients received 1 prior line of therapy and 53% received 2–3 prior lines of therapy.

Abbreviations: ASCT, autologous stem cell transplant; Cy, cyclophosphamide; D, daratumumab; d, dexamethasone; Dox, doxorubicin; E, elotuzumab; Isa, isatuximab; IMiD, immunomodulatory drug; K, carfilzomib; N, ixazomib; NMA, network meta-analyses; NR, not reported; P, pomalidomide; Pan, panobinostate; Pembro, pembrolizumab; PEG-Dox, pegylated liposomal doxorubicin; PI, proteasome inhibitor; R, lenalidomide; S, selinexor; SAE, serious adverse event; V, bortezomib; Ven, venetoclax; Vor, vorinostat
relapsed myeloma patients; however, we recommend an updated analysis be conducted taking into account the points mentioned above, and validated with clinical experts and experts in evidence synthesis.

**Declarations**

**Ethics approval** This article does not contain any studies with human participants or animals performed by any of the authors.

**Conflict of interest** Faith E. Davies reports consultancy/advisory boards for and honoraria from Bristol Myers-Squibb, Celgene, GSK, Janssen, Oncoproteptides, Sanofi, and Takeda. Patricia Guyot, François Bourhis, and Eleanor Saunders are employees and stockholders of Sanofi.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ (2018) Network meta-analysis for decision-making. Wiley, Hoboken, NJ
2. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC et al (2011) Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices; part 2. Value Health 14(4):429–437
3. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T et al (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 14(11):1129–1140
4. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331
5. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38
6. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–1634
7. Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D et al (2017) Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China continuation study. J Hematol Oncol 10(1):137
8. Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W et al (2017) Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol 96(11):1857–1866
9. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicca I et al (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621–631
10. Mateos MV, Blacklock H, Schijfsvold F, Oriol A, Simpson D, George A et al (2019) Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. The Lancet Haematology 6(9):e459–e469
11. Orlovski RZ, Nagler A, Sonneveld P, Blåd J, Hajek R, Spencer A et al (2016) Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer 122(13):2050–2056
12. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Bekscak M et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766
13. Richardson PG, Oriol A, Bekscak M, Liberator AM, Galli M, Schijfsvold F et al (2019) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISM): a randomised, open-label, phase 3 trial. Lancet Oncol 20(6):781–794
14. San-Migueł JF, Hungria VT, Yoon S-S, Bekscak M, Dimopoulos MA, Elghandour A et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195–1206
15. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicca I, Oriol A et al (2014) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142–152
16. Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasperetto C et al (2010) Venetoclax in placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLIINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21(12):1630–1642
17. Goldschmidt H, Mai EK, Dürg J, Scheid C, Weisel KC, Kunz C et al (2020) Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 34(7):1853–1865
18. Grosicki S, Simonova M, Spicca I, Pour L, Kriahoch I, Gavriatopoulou M et al (2020) Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet Oncol 21(12):1592–1601
19. Dimopoulos M, Cossig H, Mateos MV, Landgren O, Leleu X, Siegel D et al (2020) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet (London, England) 396(10254):1789–1802
20. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Bekscak M, Spicca I et al (2019) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet (London, England) 394(10214):2096–2107

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.